Tarsus Pharmaceuticals (TARS) Income from Non-Controlling Interests (2022 - 2026)
Tarsus Pharmaceuticals' (TARS) quarterly Income from Non-Controlling Interests came in at -$679000.0 in Q1 2026, down 622.34% year-on-year from $129991.9 in Q1 2025, and down 838.04% quarter-over-quarter from $92000.0 in Q4 2025.
Tarsus Pharmaceuticals (TARS) Income from Non-Controlling Interests (2022 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' Income from Non-Controlling Interests history runs 5 years deep, the most recent figure standing at -$679000.0 for Q1 2026.
- On a quarterly basis, Income from Non-Controlling Interests fell 622.34% year-over-year to -$679000.0 in Q1 2026; TTM through Mar 2026 was -$383000.0, a 358.78% decrease from a year earlier, with the FY2025 full-year figure at $202000.0, up 11.6% from the prior year.
- Income from Non-Controlling Interests declined to -$679000.0 in Q1 2026 per TARS's latest filing, from $92000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $522000.0 in Q3 2024 and bottomed at -$679000.0 in Q1 2026.
- The 5-year median for Income from Non-Controlling Interests is -$10000.0 (2022), against an average of -$19866.7.
- Biggest YoY gain for Income from Non-Controlling Interests was 3380.0% in 2024; the steepest drop was 2883.33% in 2024.
- Year by year, Income from Non-Controlling Interests stood at -$64000.0 in 2022, then jumped by 109.38% to $6000.0 in 2023, then slumped by 2883.33% to -$167000.0 in 2024, then surged by 155.09% to $92000.0 in 2025, then tumbled by 838.04% to -$679000.0 in 2026.
- Per Business Quant, the three latest TARS Income from Non-Controlling Interests figures stand at -$679000.0 (Q1 2026), $92000.0 (Q4 2025), and $250000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,071.81 Bn | - | - |
| 2 | Nanobiotix | 1,925.70 Bn | 1,925.64 Bn | - | - |
| 3 | Akari Therapeutics | 1,062.88 Bn | 1,062.88 Bn | - | - |
| 4 | BeOne Medicines | 469.09 Bn | 464.29 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 123.09 Bn | 115.84 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.32 Bn | 61.57 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 63.36 Bn | 63.36 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.71 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.69 Bn | 34.68 Bn | 959.66 Mn | - |
| 10 | Tarsus Pharmaceuticals | 2.60 Bn | 2.50 Bn | 152.66 Mn | -679,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -679,000.00 |
| Dec 31, 2025 | 92,000.00 |
| Sep 30, 2025 | 250,000.00 |
| Jun 30, 2025 | -46,000.00 |
| Mar 31, 2025 | -94,000.00 |
| Dec 31, 2024 | -167,000.00 |
| Sep 30, 2024 | 522,000.00 |
| Jun 30, 2024 | -113,000.00 |
| Mar 31, 2024 | -61,000.00 |
| Dec 31, 2023 | 6,000.00 |
| Sep 30, 2023 | 15,000.00 |
| Jun 30, 2023 | 47,000.00 |
| Mar 31, 2023 | 4,000.00 |
| Dec 31, 2022 | -64,000.00 |
| Sep 30, 2022 | -10,000.00 |